U.S. Markets closed
  • S&P 500

    3,662.45
    +40.82 (+1.13%)
     
  • Dow 30

    29,823.92
    +185.28 (+0.63%)
     
  • Nasdaq

    12,355.11
    +156.37 (+1.28%)
     
  • Russell 2000

    1,836.05
    +16.23 (+0.89%)
     
  • Crude Oil

    44.40
    -0.94 (-2.07%)
     
  • Gold

    1,813.90
    +38.20 (+2.15%)
     
  • Silver

    24.14
    +1.55 (+6.85%)
     
  • EUR/USD

    1.2076
    +0.0141 (+1.1834%)
     
  • 10-Yr Bond

    0.9340
    +0.0900 (+10.66%)
     
  • Vix

    20.77
    +0.20 (+0.97%)
     
  • GBP/USD

    1.3428
    +0.0096 (+0.7224%)
     
  • USD/JPY

    104.3080
    -0.0160 (-0.0153%)
     
  • BTC-USD

    18,965.00
    -434.77 (-2.24%)
     
  • CMC Crypto 200

    372.15
    -7.71 (-2.03%)
     
  • FTSE 100

    6,384.73
    +118.54 (+1.89%)
     
  • Nikkei 225

    26,787.54
    +353.92 (+1.34%)
     

Price Over Earnings Overview: Amphastar Pharmaceuticals

Benzinga Insights
·2 min read

 

In the current session, Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) is trading at $20.56, after a 8.2% increase. Over the past month, the stock increased by 3.79%, and in the past year, by 4.10%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 9.39%.

The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company’s current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.

View more earnings on AMPH

Most often, an industry will prevail in a particular phase of a business cycle, than other industries.

Amphastar Pharmaceuticals Inc. has a better P/E ratio of 237.5 than the aggregate P/E ratio of 3.8 of the Pharmaceuticals industry. Ideally, one might believe that Amphastar Pharmaceuticals Inc. might perform better in the future than it’s industry group, but it’s probable that the stock is overvalued.

There are many limitations to price to earnings ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.